3O8 Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Omeros Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.33 |
| 52 Week High | US$5.11 |
| 52 Week Low | US$0.98 |
| Beta | 1.48 |
| 11 Month Change | -10.68% |
| 3 Month Change | -5.13% |
| 1 Year Change | 5.58% |
| 33 Year Change | -75.10% |
| 5 Year Change | -80.77% |
| Change since IPO | -27.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3O8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -11.2% | -2.1% | -3.0% |
| 1Y | 5.6% | -16.7% | 3.5% |
Return vs Industry: 3O8 exceeded the German Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 3O8 exceeded the German Market which returned 3.5% over the past year.
Price Volatility
| 3O8 volatility | |
|---|---|
| 3O8 Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3O8's share price has been volatile over the past 3 months.
Volatility Over Time: 3O8's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 198 | Greg Demopulos | www.omeros.com |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
Omeros Corporation Fundamentals Summary
| 3O8 fundamental statistics | |
|---|---|
| Market cap | €191.08m |
| Earnings (TTM) | -€181.11m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 3O8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3O8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$85.64m |
| Gross Profit | -US$85.64m |
| Other Expenses | US$114.28m |
| Earnings | -US$199.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -339.6% |
How did 3O8 perform over the long term?
See historical performance and comparison